TL;DR
MedPage Today published a November 15, 2026, roundup of eight remarks from clinicians, researchers and health leaders on current medical and public health issues. The quotes touch on opioid treatment for sickle cell disease pain, an American Diabetes Association boycott, vaccine messaging, prostate cancer screening and other topics; the roundup does not resolve the disputes or provide new clinical guidance.
MedPage Today published a weekly roundup of health-care remarks on November 15, 2026, led by a physician’s blunt comment about opioids and sickle cell disease pain: “Opioids cause pain. Full stop.” The collection also covers an organizational boycott, a lawsuit alleging drug-safety concerns, vaccine misinformation and changes to cancer-screening guidance; it is a selection of quotes, not a report establishing new medical findings or policy decisions.
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The opioid remark came from Jeffrey Glassberg, MD, of the Icahn School of Medicine at Mount Sinai, who was commenting on opioid use to treat pain associated with sickle cell disease. The roundup offers no further detail about the setting or evidence behind his statement. It should be read as Glassberg’s characterization, not as a complete account of treatment options or a clinical recommendation.
Other comments addressed separate developments. Christian Kohler, who resigned as vice president of publications at the American Diabetes Association, said the organization’s boycotters were not acting frivolously. At the annual Liver Meeting, David Goldberg, MD, referred to a whistleblower lawsuit alleging safety concerns about resmetirom, marketed as Rezdiffra, for metabolic dysfunction-associated steatohepatitis. The roundup describes the allegations but does not establish them as fact.
The remaining remarks span sleep, public health, cancer screening and medication use. Anne Marie Morse, DO, discussed how patients with sleep disorders describe brain fog; public health leaders Georges Benjamin and Elizabeth Jacobs criticized beliefs about autism risk and a delayed federal vaccine-task-force report. Mark Ashamalla, MD, commented on updated prostate cancer screening guidance, while Rose Cairns, PhD, said pregabalin use in Australia remained too high even as a rise in gabapentinoid use showed signs of reversing.
Eight Quotes Across Health Debates
The roundup captures how clinicians and health leaders are framing several active debates, but its significance lies in the range of concerns represented, not in a single announcement. Readers encounter comments on pain treatment, organizational protest, drug safety allegations, vaccine communication, screening guidance and prescribing patterns in one short dispatch.
The distinction between a quotation and a finding matters. A forceful statement about opioids does not, by itself, establish how a particular patient with sickle cell disease should be treated. Likewise, comments about a lawsuit, a survey or a policy update do not substitute for the underlying records, study results or guidance. The roundup points readers toward issues that warrant attention while leaving their evidence and implications to be examined in fuller reporting.
Popular right now

De'Longhi Stilosa Compact Manual Espresso Machine with Milk Frother

Vitamix VX1 Professional-Grade Blender, 64 oz, Black

Sony WH-1000XM6 Wireless Noise-Canceling Headphones, Black
As an affiliate, we earn on qualifying purchases.
The Roundup’s Medical Topics
MedPage Today presents the item as a collection of notable quotations heard by its reporters during the week, rather than as a single investigation. The eight remarks cover distinct subjects and speakers, including comments connected to a medical meeting, public health organizations and clinical practice. They should not be treated as parts of one coordinated development.
The source gives brief descriptions but limited supporting detail. It does not provide the underlying research on opioids or gabapentinoids, the full terms of the diabetes organization boycott, or the whistleblower complaint about resmetirom. It also does not reproduce the complete prostate cancer screening recommendations or the vaccine-task-force report under criticism. Those materials are needed to assess the claims independently.
““This is not a frivolous exercise for the boycotters.””
— Christian Kohler, former vice president of publications at the American Diabetes Association
Claims Need More Supporting Detail
The roundup does not provide enough information to evaluate the evidence behind the opioid comment or interpret it as advice for individual patients. It also does not specify the survey methodology behind the autism-risk finding, identify the particular vaccine-task-force report in detail, or reproduce the updated screening recommendations.
The resmetirom safety concerns are described as allegations in a whistleblower lawsuit, not as findings confirmed by the roundup. Details about the diabetes boycott, including its demands and status, are also limited. The item does not say what further action, if any, followed the remarks.
Follow the Underlying Reports
The next step for readers seeking detail is to consult the underlying sources: the relevant clinical evidence and guidance on sickle cell pain, the whistleblower filing and any responses concerning resmetirom, and the full prostate cancer screening recommendations. Further reporting or statements from the organizations and officials involved may clarify the disputes described in the roundup.
The November 15 item itself announces no follow-up action and does not set out a timeline for new findings. Any changes in policy, clinical guidance or organizational positions remain outside what the published collection confirms.
Key Questions
What did MedPage Today publish?
It published a weekly collection of eight health-related quotations on November 15, 2026. The comments cover several separate clinical and public health topics.
Who made the comment about opioids and sickle cell disease?
Jeffrey Glassberg, MD, of the Icahn School of Medicine at Mount Sinai made the remark while commenting on opioid use to treat sickle cell disease pain. The roundup does not provide supporting evidence or detailed treatment guidance.
Did the report confirm safety problems with Rezdiffra?
No. It says David Goldberg referred to a whistleblower lawsuit alleging safety concerns about resmetirom, marketed as Rezdiffra. The roundup does not establish the allegations as fact.
Did the roundup announce new medical guidelines?
No. It includes a physician’s comment that the American Cancer Society was taking a clearer position after prostate cancer screening guideline updates, but it does not reproduce the recommendations or announce them itself.
Source: medpagetoday.com
